Hansa Biopharma AB: Hansa Biopharma to present data at 2024

LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant

Related Keywords

United Kingdom , United States , Sweden , Jordan , France , Stockholm , American , French , Evan Ballantyne , Hansa Biopharma , Stephanie Kenney , European Medicines Agency , American Transplant Congress , European Union , European Medicines Agency Ema Priority , Drug Administration , Vp Global Corporate Affairs , American Society Of Transplantation , American Society Of Transplant Surgeons , Linkedin , American Society , Transplant Surgeons , Biologic License Application , Guillain Barre Syndrome , Exhibit Hall , Breaking Abstracts , Clinical Rapid Fire Oral , Highly Sensitized Kidney Transplant Recipients , Positive Crossmatch Against , Deceased Donor , Kidney Transplantations Performed , Clinical Outcomes , Human Leukocyte Antigens , Product Characteristics , End Stage Renal Disease , Nasdaq Stockholm , Dial Transplant , European Medicines , Englj Med , Ihr Portfolio ,